Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,issuanceOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,postMarketChangePercent,postMarketTime,postMarketPrice,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,epsForward,currency,priceHint,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 29, 2021) 4","Short Ratio (Jun 29, 2021) 4","Short % of Float (Jun 29, 2021) 4","Short % of Shares Outstanding (Jun 29, 2021) 4","Shares Short (prior month May 27, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,HALO,67595000.0,142386000,,,28086000,,27895000,11059000,61794000,50735000,50735000,,-1965000,,,,191000,89022000,38287000,27228000,-22649000,,27895000,27895000,501186000.0,898987000.0,67595000.0,1746000.0,966582000.0,143000.0,-433725000.0,4337000.0,-9000.0,14497000.0,499450000.0,107421000.0,89042000.0,-9000.0,10366000.0,941719000.0,264856000.0,88391000.0,784731000.0,58343000.0,535000.0,-44980000.0,-6626000.0,-45250000.0,415811000.0,338701000.0,-2335000.0,351747000.0,-76781000.0,58296000.0,738000.0,2513000.0,9339000.0,-329000.0,26031000.0,-270000.0,,834298000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,-0.34000015,0.04762239,41.93 - 42.7029,41.99,0.0,0.0,18,8,finmb_7931206,NasdaqGS,"Halozyme Therapeutics, Inc.",USD,829468,801057,-0.80933154,1630530641,41.67,16.839998,0.6690504,25.17 - 56.4,-14.390003,-0.25514188,25.17,56.4,1620676800,1635764340,1636113600,37.309055,1.126,2.49,USD,2,1.66,25.307228,0.472,41.228573,0.7814255,0.018953493,43.58065,-1.570652,-0.036040124,5981635584,16.871485,89.004234,15,America/New_York,EDT,-14400000,NMS,0,False,False,42.01,1630526402,0.019996643,42.3947,42.7029,41.93,688974,"Halozyme Therapeutics, Inc.",us_market,PREPRE,1.46,,,56.4,25.17,41.23,43.58,829.47k,801.06k,142.39M,,140.92M,1.03%,95.68%,6.47M,6.17,5.28%,4.54%,6.85M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",49.23%,59.84%,16.98%,259.61%,331.26M,2.43,251.10%,189.99M,199.78M,163.08M,1.13,,764.31M,5.37,878.23M,1299.26,8.77,0.47,118.59M,44.94M,Value,92121,Healthcare,136,4,5,"Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.",San Diego,858 794 8889,CA,5,1609372800,1625097600,1,United States,http://www.halozyme.com,86400,3,11388 Sorrento Valley Road,858 704 8311,Biotechnology
t-1,HALO,151047000.0,142386000,,,73249000,,73164000,10427000,88051000,77624000,77624000,,-5036000,,,,85000,121703000,44079000,33652000,-4375000,,73164000,73164000,625483000.0,428877000.0,151047000.0,1746000.0,579924000.0,135000.0,-474593000.0,5187000.0,22000.0,14567000.0,147703000.0,421385000.0,397228000.0,22000.0,10593000.0,554764000.0,220310000.0,97730000.0,,60747000.0,1928000.0,59925000.0,-1074000.0,58441000.0,415811000.0,-27399000.0,4085000.0,81962000.0,-40147000.0,50920000.0,800000.0,-3050000.0,-35179000.0,-329000.0,8578000.0,-1699000.0,12748000.0,133379000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,-0.34000015,0.04762239,41.93 - 42.7029,41.99,0.0,0.0,18,8,finmb_7931206,NasdaqGS,"Halozyme Therapeutics, Inc.",USD,829468,801057,-0.80933154,1630530641,41.67,16.839998,0.6690504,25.17 - 56.4,-14.390003,-0.25514188,25.17,56.4,1620676800,1635764340,1636113600,37.309055,1.126,2.49,USD,2,1.66,25.307228,0.472,41.228573,0.7814255,0.018953493,43.58065,-1.570652,-0.036040124,5981635584,16.871485,89.004234,15,America/New_York,EDT,-14400000,NMS,0,False,False,42.01,1630526402,0.019996643,42.3947,42.7029,41.93,688974,"Halozyme Therapeutics, Inc.",us_market,PREPRE,1.46,,,56.4,25.17,41.23,43.58,829.47k,801.06k,142.39M,,140.92M,1.03%,95.68%,6.47M,6.17,5.28%,4.54%,6.85M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",49.23%,59.84%,16.98%,259.61%,331.26M,2.43,251.10%,189.99M,199.78M,163.08M,1.13,,764.31M,5.37,878.23M,1299.26,8.77,0.47,118.59M,44.94M,Value,92121,Healthcare,136,4,5,"Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.",San Diego,858 794 8889,CA,5,1609372800,1625097600,1,United States,http://www.halozyme.com,86400,3,11388 Sorrento Valley Road,858 704 8311,Biotechnology
t-2,HALO,98988000.0,142386000,,,36270000,,36207000,11702000,52001000,40299000,40299000,,-4990000,,,,63000,65316000,25017000,13315000,-4029000,,36207000,36207000,646184000.0,425041000.0,98988000.0,748000.0,524029000.0,135000.0,-547757000.0,641000.0,426000.0,14882000.0,65741000.0,26976000.0,,426000.0,10252000.0,498895000.0,280965000.0,62551000.0,393631000.0,57697000.0,433000.0,-30042000.0,-2610000.0,-30095000.0,415811000.0,-43854000.0,-2010000.0,-67865000.0,-56400000.0,6084000.0,803000.0,-9426000.0,-25150000.0,-329000.0,4718000.0,-176000.0,12546000.0,471919000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,-0.34000015,0.04762239,41.93 - 42.7029,41.99,0.0,0.0,18,8,finmb_7931206,NasdaqGS,"Halozyme Therapeutics, Inc.",USD,829468,801057,-0.80933154,1630530641,41.67,16.839998,0.6690504,25.17 - 56.4,-14.390003,-0.25514188,25.17,56.4,1620676800,1635764340,1636113600,37.309055,1.126,2.49,USD,2,1.66,25.307228,0.472,41.228573,0.7814255,0.018953493,43.58065,-1.570652,-0.036040124,5981635584,16.871485,89.004234,15,America/New_York,EDT,-14400000,NMS,0,False,False,42.01,1630526402,0.019996643,42.3947,42.7029,41.93,688974,"Halozyme Therapeutics, Inc.",us_market,PREPRE,1.46,,,56.4,25.17,41.23,43.58,829.47k,801.06k,142.39M,,140.92M,1.03%,95.68%,6.47M,6.17,5.28%,4.54%,6.85M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",49.23%,59.84%,16.98%,259.61%,331.26M,2.43,251.10%,189.99M,199.78M,163.08M,1.13,,764.31M,5.37,878.23M,1299.26,8.77,0.47,118.59M,44.94M,Value,92121,Healthcare,136,4,5,"Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.",San Diego,858 794 8889,CA,5,1609372800,1625097600,1,United States,http://www.halozyme.com,86400,3,11388 Sorrento Valley Road,858 704 8311,Biotechnology
t-3,HALO,105577000.0,142386000,,,25875000,,25817000,10975000,40530000,29555000,29555000,,-5004000,,,,58000,55221000,25666000,14691000,-3680000,,25817000,25817000,688318000.0,421420000.0,105577000.0,748000.0,526997000.0,137000.0,-583964000.0,641000.0,1086000.0,15470000.0,133606000.0,26073000.0,,1086000.0,11169000.0,500358000.0,251840000.0,37401000.0,390079000.0,48271000.0,4067000.0,12414000.0,-9903000.0,11899000.0,-2861000.0,13593000.0,-3390000.0,28786000.0,-1996000.0,3294000.0,824000.0,-6819000.0,-7652000.0,68000.0,907000.0,-515000.0,18382000.0,474285000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,-0.34000015,0.04762239,41.93 - 42.7029,41.99,0.0,0.0,18,8,finmb_7931206,NasdaqGS,"Halozyme Therapeutics, Inc.",USD,829468,801057,-0.80933154,1630530641,41.67,16.839998,0.6690504,25.17 - 56.4,-14.390003,-0.25514188,25.17,56.4,1620676800,1635764340,1636113600,37.309055,1.126,2.49,USD,2,1.66,25.307228,0.472,41.228573,0.7814255,0.018953493,43.58065,-1.570652,-0.036040124,5981635584,16.871485,89.004234,15,America/New_York,EDT,-14400000,NMS,0,False,False,42.01,1630526402,0.019996643,42.3947,42.7029,41.93,688974,"Halozyme Therapeutics, Inc.",us_market,PREPRE,1.46,,,56.4,25.17,41.23,43.58,829.47k,801.06k,142.39M,,140.92M,1.03%,95.68%,6.47M,6.17,5.28%,4.54%,6.85M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",49.23%,59.84%,16.98%,259.61%,331.26M,2.43,251.10%,189.99M,199.78M,163.08M,1.13,,764.31M,5.37,878.23M,1299.26,8.77,0.47,118.59M,44.94M,Value,92121,Healthcare,136,4,5,"Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.",San Diego,858 794 8889,CA,5,1609372800,1625097600,1,United States,http://www.halozyme.com,86400,3,11388 Sorrento Valley Road,858 704 8311,Biotechnology
